There is increasing evidence suggesting that NF-κB targeting could also increase tumour sensitivity to the therapy (e.g., chemo- and radiotherapy) and delay/repress the loss of therapeutic effectiveness. This evidence concerns the gene NFKB1 and neoplasm.